Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study

Keyphrases

• Group Studies 100%
• Phase II Trial 100%
• Bevacizumab 100%
• Epithelial Ovarian Cancer 100%
• Gynecologic Oncology Group 100%
• Primary Peritoneal Cancer 100%
• Adverse Events 40%
• Clinical Response 40%
• Performance Status 40%
• Monoclonal Antibody 20%
• Tumor Progression 20%
• Group Performance 20%
• Disease Progression 20%
• Overall Survival 20%
• Hypertension 20%
• Vascular Endothelial Growth Factor 20%
• Progression-free 20%
• Vomiting 20%
• Median Progression-free Survival 20%
• Tolerability 20%
• Progression-free Survival 20%
• Duration of Response 20%
• Pulmonary Embolism 20%
• Hematologic 20%
• Allergy 20%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 20%
• Measurable Disease 20%
• Constipation 20%
• Coagulation 20%
• Dyspnea 20%
• Proteinuria 20%
• Chemotherapeutic Regimens 20%
• Third-line Treatment 20%
• Thromboembolism 20%
• Second-line Treatment 20%
• Platinum Sensitivity 20%

Medicine and Dentistry

• Gynecological Oncology 100%
• Bevacizumab 100%
• Phase II Trials 100%
• Krukenberg Tumor 100%
• Primary Peritoneal Cancer 100%
• Progression Free Survival 60%
• Adverse Event 40%
• Vasculotropin 40%
• Monoclonal Antibody 20%
• Tumor Progression 20%
• Overall Survival 20%
• Promoter Region 20%
• Disease Exacerbation 20%
• Pulmonary Embolism 20%
• Dyspnea 20%
• Constipation 20%
• Thromboembolism 20%
• Proteinuria 20%
• Diseases 20%
• Chemotherapy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Phase II Trials 100%
• Ovary Carcinoma 100%
• Bevacizumab 100%
• Peritoneum Cancer 100%
• Progression Free Survival 60%
• Adverse Event 40%
• Vasculotropin 40%
• Tumor Growth 20%
• Disease Exacerbation 20%
• Overall Survival 20%
• Tolerability 20%
• Dyspnea 20%
• Monoclonal Antibody 20%
• Constipation 20%
• Proteinuria 20%
• Lung Embolism 20%
• Thromboembolism 20%
• Diseases 20%